Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), a leader in the development of differentiated targeted radiotherapies, today announced that the first-ever preclinical data from its ATNM-400 ...

Actinium Pharmaceuticals (ATNM) announced that the first-ever preclinical data from its ATNM-400 program in non-small cell lung cancer has been ...

Fusion to invest $5M for guaranteed access to actinium-225 supply Agreement augments Fusion's existing supply as company expands pipeline of actinium-based radio pharmaceuticals "As excitement for the ...

- The SIERRA results demonstrate Iomab-B's ability to overcome the negative impact of a TP53 mutation in patients who otherwise would have limited treatment options and dismal prognosis - Represents ...

Nuveen LLC bought a new position in Actinium Pharmaceuticals, Inc. (NYSE:ATNM – Free Report) during the 1st quarter, Holdings Channel reports. The institutional investor bought 148,560 shares of the ...

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) is among the best growth stocks to invest in for the next 5 years. During the Society of Nuclear Medicine & Molecular Imaging annual meeting in New Orleans, ...

NEW YORK, Nov. 7, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") announced today that it will attend the 25 th Annual BIO-Europe ® International Partnering ...

NEW YORK (AP) — NEW YORK (AP) — Actinium Pharmaceuticals Inc. (ATNM) on Friday reported a loss of $6.9 million in its second quarter. On a per-share basis, the New York-based company said it had a ...

NEW YORK, June 10, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) ...

During the Society of Nuclear Medicine & Molecular Imaging annual meeting in New Orleans, Actinium Pharmaceuticals, Inc. (NYSE:ATNM) showcased promising preclinical results for its prostate cancer ...

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) between October 31, 2022, and August 2, 2024, both dates ...